NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET
Rhea-AI Summary
NeOnc Technologies (NTHI), a clinical-stage biotech company focused on brain and central nervous system cancer treatments, announces a live interview featuring Executive Chairman Amir Heshmatpour with Kenny Polcari on YouTube.com/@Floorstocks on July 23, 2025, at 11:00 a.m. ET.
The interview follows two significant developments: the execution of a Sub-License Agreement with NuroCure for the UAE, GCC, and MENA regions as part of a $50 million strategic partnership with Quazar Investment, and the company's inclusion in the Russell Microcap Index. NeOnc's NEO100™ and NEO212™ therapeutics are currently in Phase II clinical trials with FDA Fast-Track status, targeting malignant gliomas with patent protection until 2038.
Positive
- Strategic partnership worth $50 million with Quazar Investment
- Inclusion in Russell Microcap Index, potentially increasing institutional investment and liquidity
- Two drug candidates (NEO100™ and NEO212™) in Phase II trials with FDA Fast-Track status
- Patent protection extending to 2038 for proprietary technology
Negative
- Partnership with Quazar Investment not yet finalized
- Still in clinical-stage with no commercialized products
- Dependent on successful completion of clinical trials for future growth
News Market Reaction – NTHI
On the day this news was published, NTHI gained 2.27%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $86M at that time.
Data tracked by StockTitan Argus on the day of publication.
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, is pleased to announce that its Executive Chairman & President, Amir Heshmatpour, will be featured in a live interview with prominent financial commentator Kenny Polcari on YouTube.com/@Floorstocks. The interview will air live today at 11:00 a.m. ET.
The interview comes on the heels of NeOnc’s recent execution of a Sub-License Agreement with its Abu Dhabi onshore operating subsidiary, NuroCure, a key milestone toward the company’s
NeOnc was also recently included in the Russell Microcap Index, a milestone that aligns with the company’s broader capital markets strategy to attract institutional capital, drive passive fund flows, and enhance market liquidity.
“This is an exciting time for NeOnc Technologies as we move closer to closing the
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
FAQ
What is the status of NTHI's partnership with Quazar Investment?
What stage are NeOnc Technologies' (NTHI) clinical trials in?
When will NTHI's drug patents expire?
What is the significance of NTHI joining the Russell Microcap Index?
What types of cancer does NTHI's technology target?
